The Committee on Herbal Medicinal Products (HMPC) is the committee at the European Medicines Agency that is responsible for preparing the Agency's opinions on herbal medicines.
It was established in September 2004, replacing the Committee for Proprietary Medicinal Products' Working Party on Herbal Medicinal Products, in accordance with Regulation (EC) No 726/2004 and Directive 2004/24/EC, which introduced a simplified registration procedure for traditional herbal medicines in European Union (EU) Member States.
- See the full overview of the HMPC's role.
The members of the HMPC are scientific experts in the field of herbal medicines.
The Committee has one member and one alternate member nominated by each of the 28 EU Member States and by Iceland and Norway. The chair is elected by serving HMPC members.
Up to five additional members may be co-opted to contribute additional expertise to the HMPC. These are European experts nominated by the Member States or by the Agency. Currently, the Committee has co-opted members with expertise in:
- clinical pharmacology;
- experimental / non-clinical pharmacology;
- paediatric medicine;
- general and family medicine.
The HMPC also has observers from the European Directorate for the Quality of Medicines and Healthcare (EDQM) and from Albania, Bosnia and Herzegovina, Kosovo under UNSC Resolution 1244/99, the Former Yugoslav Republic of Macedonia, Montenegro, Serbia and Turkey as part of the EU enlargement programme.
- See the full meeting plan for the HMPC.